Open access
Aug 2026
Cost-Effectiveness Analysis of the mRNA-1345 RSV Vaccine for Older Adults in Italy
Vaccination with mRNA-1345 is a cost-effective strategy for the prevention of RSV in high-risk adults aged 60-74 years and all adults aged [≥]75 years in Italy and has the potential to provide substantial public health benefits.
M. Dronova, C. Moyon, L. Pyrek et al.
· medRxiv · 0 citations